Effect of PPlD-1, a Synthetic Antiplatelet Compound, on Rabbit Platelets
Open Access
- 1 January 1998
- journal article
- Published by Elsevier in The Japanese Journal of Pharmacology
- Vol. 76 (2) , 141-148
- https://doi.org/10.1254/jjp.76.141
Abstract
The antiplatelet mechanism of a synthetic compound, 2-chloro-3-methoxycarbonylpropionamido-1,4-naphthoquinone (PP1D-1), was studied by employing washed rabbit platelets in vitro. PP1D-1 concentration-dependently inhibited thrombin (0.1 U/ml)-, platelet-activating factor (2 ng/ml)-, collagen (10 microg/ml)-, arachidonic acid (100 microM)- and U46619 (1 microM)-induced aggregation and ATP release in washed rabbit platelets. The IC50 values of PP1D-1 for aggregation induced by the above inducers are 17.9+/-1.7, 9.8+/-1.1, 3.9+/-0.4, 1.8+/-0.3 and 1.7+/-0.3 microM, respectively. PP1D-1 did not affect platelet thromboxane B2 or prostaglandin D2 formation induced by arachidonic acid, indicating that it did not affect cyclooxygenase and thromboxane synthase activities. PP1D-1 significantly inhibited the formation of inositol 1,4,5-trisphosphate caused by these five platelet stimulators. Moreover, PP1D-1 inhibited the increase in intracellular calcium concentration induced by these agents. On the contrary, PP1D-1 did not inhibit thapsigargin-elevated intracellular calcium concentration in indomethacin-pretreated platelets, indicating it did not influence the effect of thapsigargin. According to these data, PP1D-1 exerts antiplatelet effects mainly by inhibiting phosphoinositide turnover.Keywords
This publication has 29 references indexed in Scilit:
- Antithrombotic nipecotamide increases cyclic AMP levels and inhibits protein phosphorylation in human plateletsLife Sciences, 1995
- Antiplatelet DrugsDrugs, 1995
- Thrombolysis in Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Role of ticlopidine for prevention of stroke.Stroke, 1992
- Platelet Hyperreactivity and Prognosis in Survivors of Myocardial InfarctionNew England Journal of Medicine, 1990
- The calcium mobilizing and tumor promoting agent, thapsigargin elevates the platelet cytoplasmic free calcium concentration to a higher steady state level. A possible mechanism of action for the tumor promotionBiochemical and Biophysical Research Communications, 1987
- Thromboembolism and antithrombotic therapy in cerebrovascular diseaseJournal of the American College of Cardiology, 1986
- Thrombin and ionomycin can raise platelet cytosolic Ca2+ to micromolar levels by discharge of internal Ca2+ stores: Studies using fura-2Biochemical and Biophysical Research Communications, 1986
- Cytoplasmic free Ca2+ in human platelets: Ca2+ thresholds and Ca‐independent activation for shape‐change and secretionFEBS Letters, 1982
- XIV. Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Study group on antithrombotic therapy.Stroke, 1977